Skip to main content
SpringerLink
Log in

Locally Advanced and Metastatic Gastric Cancer

Current Management and New Treatment Developments

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The management of gastric cancer remains a challenge. In recent years, the most important advances have been achieved in the adjuvant setting for patients with locally advanced disease, where significant survival benefits have been demonstrated for both perioperative chemotherapy and adjuvant chemoradiotherapy. These findings have changed the standard of care for patients with resectable disease.

In the setting of metastatic gastric cancer, the development of new cytotoxic regimens must consider the balance between efficacy and toxicity in patients whose overall prognosis is poor. Major advances in recent years include the development of orally administered fluoropyrimidine analogues, which can be used in place of intravenous fluorouracil, and the addition of newer agents such as oxaliplatin and docetaxel, which have demonstrated efficacy in patients with advanced disease. Targeted therapies have had a major impact on the management of certain malignancies, and while their evaluation in the treatment of advanced gastric cancer remains early, it is likely that these agents will continue to be developed and studied in combination with chemotherapy.

This article reviews recent advances in the use of chemotherapy for advanced gastric cancer. Targeted therapies, their mechanisms of action and emerging data supporting their use in gastric cancer are also discussed. The two randomized phase III trials supporting adjuvant therapy for locally advanced, resectable gastric cancer are discussed in detail, together with strategies for future trials in this area. Overall, there remains optimism that further incremental gains will be achieved with future studies combining chemotherapy, radiotherapy and targeted therapies, both in the adjuvant and metastatic disease settings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. National Cancer Institute. Surveillance epidemiology and end results: cancer of the stomach [online]. Available from URL: http://seer.cancer.gov/statfacts/html/stomach.html [Accessed 2007 Dec 19]

  2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74–108

    PubMed  Google Scholar 

  3. Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005; 10 Suppl. 3: 49–58

    Google Scholar 

  4. Khamly K, Jefford M, Michael M, et al. Recent developments in the systemic therapy of advanced gastroesophageal malignancies. Expert Opin Investig Drugs 2006; 15(2): 131–53

    PubMed  CAS  Google Scholar 

  5. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol 2004; 31(4): 450–64

    PubMed  Google Scholar 

  6. Lynch HT, Smyrk TC, Watson P, et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 1993; 104(5): 1535–49

    PubMed  CAS  Google Scholar 

  7. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993; 71(3): 677–85

    PubMed  CAS  Google Scholar 

  8. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392(6674): 402–5

    PubMed  CAS  Google Scholar 

  9. Richards FM, McKee SA, Rajpar MH, et al. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet 1999; 8(4): 607–10

    PubMed  CAS  Google Scholar 

  10. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31–49

    PubMed  CAS  Google Scholar 

  11. Haruma K, Okamoto S, Kawaguchi H, et al. Reduced incidence of Helicobacter pylori infection in young Japanese persons between the 1970s and the 1990s. J Clin Gastroenterol 1997; 25(4): 583–6

    PubMed  CAS  Google Scholar 

  12. Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 1992; 102(3): 760–6

    PubMed  CAS  Google Scholar 

  13. Wagner AD, Grothe W, Behl S, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2005; (2): CD004064

    PubMed  Google Scholar 

  14. Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24(18): 2903–9

    PubMed  CAS  Google Scholar 

  15. Al-Batran SE, Jager E, Scholz M. Chemotherapy for advanced gastric cancer. J Clin Oncol 2007; 25(6): 729; author reply 730

    PubMed  Google Scholar 

  16. Ajani JA. Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol 2000; 18(23): 4001–3

    PubMed  CAS  Google Scholar 

  17. Ilson DH. Epirubicin, cisplatin, and fluorouracil in gastric and esophageal cancer: a step ahead? J Clin Oncol 2002; 20(8): 1962–4

    PubMed  Google Scholar 

  18. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15(1): 261–7

    PubMed  CAS  Google Scholar 

  19. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20(8): 1996–2004

    PubMed  CAS  Google Scholar 

  20. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18(14): 2648–57

    PubMed  CAS  Google Scholar 

  21. Icli F, Celik I, Aykan F, et al. A randomized phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group. Cancer 1998; 83(12): 2475–80

    PubMed  CAS  Google Scholar 

  22. Al-Batran SE. A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP) [abstract no. LBA4016]. Proceedings of the American Society of Clinical Oncology; Atlanta (GA); 2006 Jun 2–6

  23. Cunningham D. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: the REAL 2 trial [abstract no. LBA4017]. Proceedings of the American Society of Clinical Oncology; Atlanta (GA); 2006 Jun 2–6

  24. Elsaid AA. Final results of a randomized phase III trial of docetaxel, carboplatin and 5FU versus epirubicin, cisplatin and 5FU for locally advanced gastric cancer [abstract no. 4014]. Proceedings of the American Society of Clinical Oncology; Orlando (FL); 2005 May 13–17

  25. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24(31): 4991–7

    PubMed  Google Scholar 

  26. Murad AM, Petroianu A, Guimaraes RC, et al. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. Am J Clin Oncol 1999; 22(6): 580–6

    PubMed  CAS  Google Scholar 

  27. Kollmannsberger C, Quietzsch D, Haag C, et al. A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000; 83(4): 458–62

    PubMed  CAS  Google Scholar 

  28. Honecker F, Kollmannsberger C, Quietzsch D, et al. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs 2002; 13(5): 497–503

    PubMed  CAS  Google Scholar 

  29. Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J Clin Oncol 2004; 22(21): 4319–28

    PubMed  CAS  Google Scholar 

  30. Moehler M, Eimermacher A, Siebler J, et al. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005; 92(12): 2122–8

    PubMed  CAS  Google Scholar 

  31. Pozzo C, Barone C, Szanto J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 2004; 15(12): 1773–81

    PubMed  CAS  Google Scholar 

  32. Dank M. Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients [abstract no. 4003]. Proceedings of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL)

  33. Kang Y. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (ACG): efficacy and safety results [abstract no. LBA4018]. Proceedings of the American Society of Clinical Oncology; 2006 Jun 2–6; Atlanta (GA)

  34. Wagner AD, Wedding U, Kuss O, et al. Docetaxel for advanced gastric cancer? J Clin Oncol 2007; 25(17): 2490–1; author reply 2491-3

    PubMed  Google Scholar 

  35. Ilson DH. Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J Clin Oncol 2007; 25(22): 3188–90

    PubMed  CAS  Google Scholar 

  36. Kim YH, Shin SW, Kim BS, et al. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 1999; 85(2): 295–301

    PubMed  CAS  Google Scholar 

  37. Shin SJ, Chun SH, Kim KO, et al. The efficacy of paclitaxel and cisplatin combination chemotherapy for the treatment of metastatic or recurrent gastric cancer: a multicenter phase II study. Korean J Intern Med 2005; 20(2): 135–40

    PubMed  CAS  Google Scholar 

  38. Louvet C, Andre T, Tigaud JM, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002; 20(23): 4543–8

    PubMed  CAS  Google Scholar 

  39. Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004; 22(4): 658–63

    PubMed  CAS  Google Scholar 

  40. Chao Y, Yeh KH, Chang CJ, et al. Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer 2004; 91(3): 453–8

    PubMed  CAS  Google Scholar 

  41. De Vita F, Orditura M, Matano E, et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005; 92(9): 1644–9

    PubMed  Google Scholar 

  42. Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005; 92(11): 1976–83

    PubMed  CAS  Google Scholar 

  43. Starling NRS, Normal R, Iveson T, et al. Analysis of thrombo-embolic events (TEs) in the REAL-2 randomised controlled (RCT) study of four chemotherapy regimens for the treatment of oesophagogastric (OG) cancers [abstract no. 74]. American Society of Clinical Oncology Gastrointestinal Cancers Symposium; 2007 Jan 19–21; Orlando (FL)

  44. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343(13): 905–14

    PubMed  CAS  Google Scholar 

  45. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355(9209): 1041–7

    PubMed  CAS  Google Scholar 

  46. Kuehr T, Ruff P, Rapoport BL, et al. Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. BMC Cancer 2004; 4: 36

    PubMed  Google Scholar 

  47. Papamichael D. The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status. Oncologist 1999; 4(6): 478–87

    PubMed  CAS  Google Scholar 

  48. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004; 90(6): 1190–7

    PubMed  Google Scholar 

  49. Ajani J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 2006; 107(2): 221–31

    PubMed  CAS  Google Scholar 

  50. Hong YS, Song SY, Lee SI, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 2004; 15(9): 1344–7

    PubMed  CAS  Google Scholar 

  51. Koizumi W, Saigenji K, Ujiie S, et al. A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 2003; 64(3): 232–6

    PubMed  CAS  Google Scholar 

  52. Sakamoto J, Chin K, Kondo K, et al. Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer. Anticancer Drugs 2006; 17(2): 231–6

    PubMed  CAS  Google Scholar 

  53. Yeon Hee P. A prospective phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer [abstract no. 1232]. Proceedings of the American Society of Clinical Oncology; 2003 May 31–Jun 3; Chicago (IL)

  54. Assersohn L. Phase II trial evaluating capecitabine and irinotecan in patients with esophago-gastric carcinoma having progressed or relapsed within 3 months of platinum-based chemotherapy [abstract no. 4170]. Proceedings of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL)

  55. Takeyoshi I. A phase II study of weekly paclitaxel and doxifluridine (an intermediate metabolite of capecitabine) combination chemotherapy for advanced/recurrent gastric cancer [abstract no. 4082]. Proceedings of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL)

  56. Ajani JA. Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. Gan To Kagaku Ryoho 2006; 33 Suppl. 1: 117–20

    PubMed  CAS  Google Scholar 

  57. Diasio RB. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology (Williston Park) 1998; 12 (10 Suppl. 7): 23–7

    CAS  Google Scholar 

  58. Maehara Y. S-1 in gastric cancer: a comprehensive review. Gastric Cancer 2003; 6 Suppl. 1: 2–8

    PubMed  Google Scholar 

  59. Shitara K, Sakata Y, Kudou T, et al. S-1 for gastric cancer-S-1 monotherapy and its progress [in Japanese]. Gan To Kagaku Ryoho 2006; 33 Suppl. 1: 43–51

    Google Scholar 

  60. Sakata Y, Ohtsu A, Horikoshi N, et al. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34(11): 1715–20

    PubMed  CAS  Google Scholar 

  61. Koizumi W, Kurihara M, Nakano S, et al. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000; 58(3): 191–7

    PubMed  CAS  Google Scholar 

  62. Koizumi W, Tanabe S, Saigenji K, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003; 89(12): 2207–12

    PubMed  CAS  Google Scholar 

  63. Shitara K, Ishiguro A, Munakata M, et al. Retrospective analysis of stage IV advanced gastric cancer treated with S-1 or other chemotherapy. Int J Clin Oncol 2006; 11(5): 367–74

    PubMed  Google Scholar 

  64. Chollet P, Schoffski P, Weigang-Kohler K, et al. Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer: a trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 2003; 39(9): 1264–70

    PubMed  CAS  Google Scholar 

  65. Ajani JA, Lee FC, Singh DA, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24(4): 663–7

    PubMed  CAS  Google Scholar 

  66. Kim YH, Cheong SK, Lee JD, et al. Phase II trial of oral UFT and leucovorin in advanced gastric carcinoma. Am J Clin Oncol 1996; 19(2): 212–6

    PubMed  CAS  Google Scholar 

  67. Ravaud A, Borner M, Schellens JH, et al. UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer: an Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial. Eur J Cancer 2001; 37(13): 1642–7

    PubMed  CAS  Google Scholar 

  68. Jeen YT, Yoon SY, Shin SW, et al. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Cancer 2001; 91(12): 2288–93

    PubMed  CAS  Google Scholar 

  69. Woo IS, Moon DH, Shim BY, et al. A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma. Jpn J Clin Oncol 2005; 35(1): 13–7

    PubMed  Google Scholar 

  70. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21(1): 54–9

    PubMed  CAS  Google Scholar 

  71. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24(33): 5201–6

    PubMed  CAS  Google Scholar 

  72. Enzinger PC, Fidias J, Meyerhardt J, et al. Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer [abstract no. 68]. ASCO Gastrointestinal Cancer Symposium; 2006 Jan 26–28; San Francisco (CA)

  73. Stein A, Al-Batran E, Arnold D, et al. Cetuximab with irinotecan as salvage therapy in heavily pretreated patients with metastatic gastric cancer [abstract no. 47]. ASCO Gastrointestinal Cancers Symposium; 2007 Jan 19–21; Orlando (FL)

  74. Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007; 18(3): 510–7

    PubMed  CAS  Google Scholar 

  75. Pinto C, Difabio F, Siana S, et al. Phase II study of cetuximab in combination with FOLFIRI as first-line treatment in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study): preliminary results [abstract no. 65]. ASCO Gastrointestinal Cancer Symposium; 2006 Jan 26–28; San Francisco (CA)

  76. Doi T. Efficacy, tolerability and pharmacokinetics of gefitinib (’Iressa, ZD1839) in pretreated patients with metastatic gastric cancer [abstract no. 1036]. Proceedings of the American Society of Clinical Oncology; 2003 May 31–Jun 3; Chicago (IL)

  77. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24(30): 4922–7

    PubMed  CAS  Google Scholar 

  78. Ocean AJ. Recent results of phase II study of PS-341 (bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas [abstract no. 45]. Am Soc Clin Oncol Gastrointestinal Cancers Symposium; 2007 Jan 19–21; Orlando (FL)

  79. Eroglu A, Demirci S, Ayyildiz A, et al. Serum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancer. Br J Cancer 1999; 80(10): 1630–4

    PubMed  CAS  Google Scholar 

  80. Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 2002; 236(1): 37–42

    PubMed  Google Scholar 

  81. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21(1): 60–5

    PubMed  CAS  Google Scholar 

  82. UK Clinical Research Network. ST03: a randomised phase III trial of peri-operative chemotherapy with or without bevacizumab in operable adenocarcinoma of the stomach and gastro-oesophageal junction [online]. Available from URL: http://pfsearch.ukcrn.org.Uk/StudyDetail.aspx?TopicID=1&-studyid=1752 [Accessed 2007 Dec 19]

  83. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19(3): 183–232

    PubMed  CAS  Google Scholar 

  84. Rojo F, Tabernero J, Albaneil J, et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006; 24(26): 4309–16

    PubMed  CAS  Google Scholar 

  85. Yonemura Y, Oyama S, Kimura H, et al. Correlation of p105 expression and malignancy in gastric cancers [in Japanese]. Nippon Geka Gakkai Zasshi 1991; 92(2): 118–21

    PubMed  CAS  Google Scholar 

  86. Yonemura Y, Ohoyama S, Kimura H, et al. The expression of proliferative-associated nuclear antigen p105 in gastric carcinoma. Cancer 1991; 67(10): 2523–8

    PubMed  CAS  Google Scholar 

  87. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001; 19(5): 554–68

    PubMed  CAS  Google Scholar 

  88. Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16(2): 273–8

    PubMed  CAS  Google Scholar 

  89. Ougolkov A, Yamashita K, Bilim V, et al. Abnormal expression of E-cadherin, beta-catenin, and c-erbB-2 in advanced gastric cancer: its association with liver metastasis. Int J Colorectal Dis 2003; 18(2): 160–6

    PubMed  Google Scholar 

  90. Rebischung C, Barnoud R, Stefani L, et al. The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein. Gastric Cancer 2005; 8(4): 249–52

    PubMed  Google Scholar 

  91. Inui T, Asakawa A, Morita Y, et al. HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer. J Intern Med 2006; 260(5): 484–7

    PubMed  CAS  Google Scholar 

  92. Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993; 11(8): 1441–7

    PubMed  CAS  Google Scholar 

  93. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35(7): 1059–64

    PubMed  CAS  Google Scholar 

  94. Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GIS-CAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol 2000; 11(7): 837–43

    PubMed  CAS  Google Scholar 

  95. Janunger KG, Hafstrom L, Nygren P, et al. A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 2001; 40(2-3): 309–26

    PubMed  CAS  Google Scholar 

  96. Cascinu S, Labianca R, Barone C, et al. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst 2007; 99(8): 601–7

    PubMed  CAS  Google Scholar 

  97. Bajetta E, Buzzoni R, Mariani L, et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 2002; 13(2): 299–307

    PubMed  CAS  Google Scholar 

  98. Bouche O, Ychou M, Burtin P, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 2005; 16(9): 1488–97

    PubMed  CAS  Google Scholar 

  99. Nitti D, Wils J, Dos Santos JG, et al. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer: a combined analysis of the EORTC GI Group and the ICCG. Ann Oncol 2006; 17(2): 262–9

    PubMed  CAS  Google Scholar 

  100. De Vita G, Giuliani F, Orditura M, et al. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol 2007; 18: 1354–8

    PubMed  Google Scholar 

  101. Imanaga H, Nakazato H. Rseults of surgery for gastric cancer and effect of adjuvant mitomycin C on cancer recurrence. World J Surg 1977; 2(1): 213–21

    PubMed  CAS  Google Scholar 

  102. Maehara Y, Moriguchi S, Sakaguchi Y, et al. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J Surg Oncol 1990; 45(3): 169–72

    PubMed  CAS  Google Scholar 

  103. Sakamoto J, Tsuburaya T, Morita S, et al. Adjuvant chemotherapy with tegafur/uracil (UFT) for gastric cancer: a meta-analysis of centrally randomized clinical trials [abstract no. 4033]. Proceedings of the American Society of Clinical Oncology; 2006 Jun 2–5; Atlanta (GA)

  104. Sasako M, Yamaguchi T, Kinoshita T, et al. Randomized phase III trial comparing S-1 monotherapy versus surgery alone for stage II/III gastric cancer patients (pts) after curative D2 gastrectomy (ACTS-GC study) [abstract no. 8]. American Society of Clinical Oncology Gastrointestinal Cancers Symposium; 2007 Jan 19–21; Orlando (FL)

  105. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345(10): 725–30

    PubMed  CAS  Google Scholar 

  106. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355(1): 11–20

    PubMed  CAS  Google Scholar 

  107. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340(12): 908–14

    PubMed  CAS  Google Scholar 

  108. Cascinu S, Scartozzi M, Barone C, et al. Response: re: adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst 2007; 99(17): 1346–7

    Google Scholar 

  109. Fazio N, Biffi R, Curigliano G, et al. Re: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst 2007; 99(17): 1345–6; author reply 1346-7

    PubMed  Google Scholar 

  110. Hartgrink HH, van de Velde CJ, Putter H, et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004; 30(6): 643–9

    PubMed  CAS  Google Scholar 

  111. Leong T, Michael M, Foo K, et al. Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation. Br J Cancer 2003; 89(8): 1433–8

    PubMed  CAS  Google Scholar 

  112. Fuchs C, Fitzgerald T, Mamon II, et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal adenocarcinoma using epirubicin, cisplatin and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): a multicenter pilot study [abstract no. 1029]. Proceedings of the American Society of Clinical Oncology; 2003 May 31–Jun 3; Chicago (IL)

  113. National Cancer Institute. Phase III randomized study of adjuvant chemoradiation after resection in patients with gastric or gastroesophageal adenocarcinoma [online]. Available from URL: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=258787&version=patient&protocolsearchid=3923416 [Accessed 2007 Dec 19]

  114. Komaki R, Janjan NA, Ajani JA, et al. Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors. Oncology (Williston Park) 2000; 14 (12 Suppl. 14): 34–7

    CAS  Google Scholar 

  115. Safran H, Wanebo HJ, Hesketh PJ, et al. Paclitaxel and concurrent radiation for gastric cancer. Int J Radiat Oncol Biol Phys 2000; 46(4): 889–94

    PubMed  CAS  Google Scholar 

  116. Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004; 22(14): 2774–80

    PubMed  CAS  Google Scholar 

  117. Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 2006; 24(24): 3953–8

    PubMed  CAS  Google Scholar 

  118. Ruzzo A, Graziano F, Kawakami K, et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 2006; 24(12): 1883–91

    PubMed  CAS  Google Scholar 

  119. Ajani JA, Randolph Hecht J, Ho L, et al. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer 2006; 106(9): 1908–16

    PubMed  CAS  Google Scholar 

  120. Elit L, Oliver TK, Covens A, et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer 2007; 109(4): 692–702

    PubMed  CAS  Google Scholar 

  121. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354(1): 34–43

    PubMed  CAS  Google Scholar 

  122. Sugarbaker PH. Adjuvant intraperitoneal chemotherapy for advanced primary gastric cancer. Scand J Surg 2006; 95(4): 270–3

    PubMed  CAS  Google Scholar 

  123. Cheong JH, Shen JY, Song CS, et al. Early postoperative intraperitoneal chemotherapy following cytoreductive surgery in patients with very advanced gastric cancer. Ann Surg Oncol 2007; 14(1): 61–8

    PubMed  Google Scholar 

  124. De Roover A, Detroz B, Detry O, et al. Adjuvant hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) associated with curative surgery for locally advanced gastric carcinoma: an initial experience. Acta Chir Belg 2006; 106(3): 297–301

    PubMed  Google Scholar 

  125. Pan MH, Chang YH, Badmaev V, et al. Pterostilbene induces apoptosis and cell cycle arrest in human gastric carcinoma cells. J Agric Food Chem 2007; 55(19): 7777–85

    PubMed  CAS  Google Scholar 

  126. Pan MH, Lai CS, Hsu PC, et al. Acacetin induces apoptosis in human gastric carcinoma cells accompanied by activation of caspase cascades and production of reactive oxygen species. J Agric Food Chem 2005; 53(3): 620–30

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the contents of this review. No other persons have made substantial contributions to the work.

Author information

Authors and Affiliations

  1. Peter MacCallum Cancer Centre, Locked Bag 1, A’Beckett Street, East Melbourne, Victoria, 8006, Australia

    Kathryn Field, Michael Michael &  Trevor Leong

  2. University of Melbourne, Melbourne, Victoria, Australia

    Trevor Leong

Authors
  1. Kathryn Field
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Michael
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Trevor Leong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Trevor Leong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Field, K., Michael, M. & Leong, T. Locally Advanced and Metastatic Gastric Cancer. Drugs 68, 299–317 (2008). https://doi.org/10.2165/00003495-200868030-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200868030-00004

Keywords

Search

Navigation